Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q1 2016 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Jazz Pharmaceuticals PLC | 3 | Q2 2024 | 11.9% |
Ascendis Pharma A/S | 3 | Q2 2024 | 8.3% |
Cytokinetics Inc | 3 | Q2 2024 | 12.5% |
Soleno Therapeutics Inc | 3 | Q2 2024 | 5.5% |
Globus Medical Inc | 3 | Q2 2024 | 4.6% |
Insmed Inc | 3 | Q2 2024 | 3.7% |
ALX Oncology Holdings Inc | 3 | Q2 2024 | 2.6% |
uniQure NV | 3 | Q2 2024 | 2.8% |
Applied Therapeutics Inc | 3 | Q2 2024 | 2.9% |
Immatics NV | 3 | Q2 2024 | 2.4% |
View Vestal Point Capital, LP's complete holdings history.
Latest filings
Type | Filed |
---|---|
N-PX | 2024-08-29 |
13F-HR | 2024-08-14 |
13F-HR | 2024-05-14 |
13F-HR | 2024-02-13 |
SC 13G | 2024-02-13 |
SC 13G | 2024-02-13 |
SC 13G | 2024-02-13 |
View Vestal Point Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.